OTCMKTS:ERBA - ERBA Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.42 +0.03 (+7.69 %)
(As of 08/19/2018 05:26 AM ET)
Previous Close$0.42
Today's Range$0.3850 - $0.44
52-Week Range$0.1010 - $0.42
Volume7,753 shs
Average Volume13,171 shs
Market Capitalization$18.04 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06
ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures, and markets diagnostic test kits or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing. It manufactures scientific and laboratory instruments, such as Mago 4, Mago 4S, and Mago Plus systems, which perform tests in an automated mode; sells other diagnostic products manufactured by third parties in Italy; and develops, manufactures, and markets raw materials, such as antigens that are used in the production of diagnostic kits. The company also develops, manufactures, and markets autoimmune reagents and research products for use by research laboratories and commercial diagnostic manufacturers. In addition, the company provides instruments for blood cell counting and blood analysis; supplies reagents and other consumable materials; sells diabetic testing products, including the DS5 instrument, dispenser, and associated reagent kits, which measure long-term glucose control in diabetic patients; and offers equipment for use in the field of human and veterinary hematology. Further, it manufactures and sells liquid stable, diagnostics chemistry reagents used for in vitro diagnostics testing. The company markets its products through its sales force to hospitals, reference laboratories, clinical laboratories, and research laboratories, as well as to other commercial companies that manufacture diagnostic products in the United States; and through sales representatives and independent agents in Italy, as well as through independent distributors internationally. The company was founded in 1980 and is headquartered in Miami Lakes, Florida. ERBA Diagnostics, Inc. is a subsidiary of ERBA Diagnostics Mannheim GmbH.

Receive ERBA News and Ratings via Email

Sign-up to receive the latest news and ratings for ERBA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ERBA
CUSIPN/A
Phone305-324-2300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares48,750,000
Market Cap$18.04 million

ERBA Diagnostics (OTCMKTS:ERBA) Frequently Asked Questions

What is ERBA Diagnostics' stock symbol?

ERBA Diagnostics trades on the OTCMKTS under the ticker symbol "ERBA."

How were ERBA Diagnostics' earnings last quarter?

ERBA Diagnostics Inc (OTCMKTS:ERBA) released its earnings results on Wednesday, August, 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.01. The business had revenue of $5.90 million for the quarter, compared to analysts' expectations of $5.16 million. View ERBA Diagnostics' Earnings History.

Who are some of ERBA Diagnostics' key competitors?

Who are ERBA Diagnostics' key executives?

ERBA Diagnostics' management team includes the folowing people:
  • Mr. Suresh Vazirani, Exec. Chairman & MD (Age 68)
  • Mr. David Barka, Interim Chief Exec. Officer (Age 37)
  • Dr. Chandra Krishnan, Sr. VP of Global Sales, Marketing and Bus. Devel.
  • Mr. Ray Earl, VP of Sales - Diamedix Corp

Has ERBA Diagnostics been receiving favorable news coverage?

News stories about ERBA stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ERBA Diagnostics earned a coverage optimism score of 0.12 on Accern's scale. They also gave press coverage about the company an impact score of 45.89 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for ERBA Diagnostics.

How do I buy shares of ERBA Diagnostics?

Shares of ERBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ERBA Diagnostics' stock price today?

One share of ERBA stock can currently be purchased for approximately $0.42.

How big of a company is ERBA Diagnostics?

ERBA Diagnostics has a market capitalization of $18.04 million.

How can I contact ERBA Diagnostics?

ERBA Diagnostics' mailing address is 14100 Nw 57th Court, Miami Lakes FL, 33014. The company can be reached via phone at 305-324-2300 or via email at [email protected]


MarketBeat Community Rating for ERBA Diagnostics (OTCMKTS ERBA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about ERBA Diagnostics and other stocks. Vote "Outperform" if you believe ERBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.